ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1842

Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus: Post Hoc Analyses of Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial

Anca Askanase1, George Wan2, Mary Panaccio2, Enxu Zhao2, Julie Zhu2, Roman Bilyk2 and Richard Furie3, 1Columbia University College of Physicians and Surgeons, New York, NY, 2Mallinckrodt Pharmaceuticals, Bedminster, NJ, 3Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY

Meeting: ACR Convergence 2020

Keywords: clinical trial, Patient reported outcomes, Randomized Trial, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: SLE – Treatment Poster II

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Repository corticotropin injection (RCI, Mallinckrodt Pharmaceuticals) is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides approved for the treatment of SLE flares and as maintenance therapy. This post hoc analysis of patient-reported outcomes (PROs) from a multicenter, double-blind, randomized, placebo (PBO)-controlled study of RCI in patients with persistently active SLE despite use of moderate-dose glucocorticoids (GCs) was conducted to assess RCI-dependent quality of life (QOL) improvements (NCT02953821).

Methods: Patients were ≥18 years old with active SLE (≥4 of 11 ACR criteria; SLEDAI-2000 [SLEDAI-2K] ≥6) and moderate-severe rash and/or arthritis by BILAG despite stable GC doses (7.5-30 mg/d prednisone equivalent), antimalarials, NSAIDs for ≥4 weeks (Ws), and/or immunosuppressants for ≥8 Ws before screening. Patients were randomized to 80 U RCI subcutaneously or PBO every other day to W4 followed by twice-weekly dosing to W24. Stable GC doses were required through W16 with optional taper from W16 to W24. Primary analyses evaluated the change from baseline (BL) in the LupusQOL and Work Productivity and Activity Impairment (WPAI)-Lupus questionnaires through W24. Post hoc analyses stratified these results by BL SLEDAI-2K (< 10 vs ≥10), Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity [CLASI-A (< 11 vs ≥11)], and BILAG (< 20 vs ≥20) scores and by BILAG-based Combined Lupus Assessment (BICLA) response (patients with BICLA responses at both W20 and W24). Analyses were performed in the modified intention-to-treat population (mITT-P; patients who received ≥1 dose of study drug and contributed any post-BL efficacy data).

Results: The mITT-P (RCI, n=84; PBO, n=85) was predominantly female (91.7%) with a mean age of 39.7 years, mean BL GC dose of 11.1 mg, and mean BL SLEDAI-2K score of 9.9. RCI treatment resulted in significantly greater improvement in the LupusQOL pain domain at W16 and planning domain at W24 compared with PBO (Figure 1) and exceeded the minimal clinically important difference at all time points. Post hoc analyses demonstrated significant improvements in the pain, planning, and fatigue domains at multiple time points in RCI-treated patients with higher disease activity by BL SLEDAI-2K, CLASI-A, and BILAG and in BICLA responders (Figure 2). No significant differences between treatment groups were observed for any WPAI-Lupus parameter through W24 in the primary analysis or with higher disease activity in post hoc SLEDAI-2K, BILAG, or CLASI-A subgroups. However, RCI treatment resulted in significant improvements in percent work time missed at W24 in patients with BL CLASI-A < 11 (RCI mean change –8.4 [standard deviation (SD) 25.1]; PBO mean change 7.8 [SD 21.9]; p=0.0182 for least square mean difference) and in percent impairment while working at W16 in BICLA responders compared with PBO (Figure 3).

Conclusion: RCI treatment resulted in greater improvements in several PROs compared with PBO. These results suggest that treatment with RCI may improve QOL and work productivity in patients who have persistently active SLE despite treatment with standard SLE therapy, particularly in those with higher disease activity.


Disclosure: A. Askanase, GlaxoSmithKline, 2, 5, AstraZeneca, 2, 5, AbbVie, 5, Bristol Myers Squibb, 5, Janssen, 2, Eli Lilly, 2, Pfizer, 2, LuCIN, 2, Mallinckrodt Pharmaceuticals, 2; G. Wan, Mallinckrodt Pharmaceuticals, 3; M. Panaccio, Mallinckrodt Pharmaceuticals, 3; E. Zhao, Mallinckrodt Pharmaceuticals, 3; J. Zhu, Mallinckrodt Pharmaceuticals, 3; R. Bilyk, Mallinckrodt Pharmaceuticals, 3; R. Furie, AstraZeneca/MedImmune, 2, 5.

To cite this abstract in AMA style:

Askanase A, Wan G, Panaccio M, Zhao E, Zhu J, Bilyk R, Furie R. Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus: Post Hoc Analyses of Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/repository-corticotropin-injection-acthar-gel-for-persistently-active-systemic-lupus-erythematosus-post-hoc-analyses-of-patient-reported-outcomes-from-a-phase-4-multicenter-randomized-doub/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/repository-corticotropin-injection-acthar-gel-for-persistently-active-systemic-lupus-erythematosus-post-hoc-analyses-of-patient-reported-outcomes-from-a-phase-4-multicenter-randomized-doub/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology